Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer

被引:71
作者
Eulau, SM
Tate, DJ
Stamey, TA
Bagshaw, MA
Hancock, SL
机构
[1] Stanford Univ, Med Ctr, Dept Radiat Oncol, Stanford, CA 94305 USA
[2] Stanford Univ, Med Ctr, Dept Urol, Stanford, CA 94305 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1998年 / 41卷 / 04期
关键词
prostatic neoplasms; postoperative radiotherapy; adjuvant therapy; hormonal therapy; androgen deprivation;
D O I
10.1016/S0360-3016(98)00127-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate whether transient androgen deprivation improves outcome in patients irradiated after radical prostatectomy for locally advanced disease, persistent or rising postoperative prostate specific antigen (PSA), or local recurrence, Methods and Materials: Records of 105 consecutive patients who were treated with pelvic irradiation after radical retropubic prostatectomy between August 1985 and December 1995 were reviewed. Seventy-four patients received radiation alone (mean follow up: 4.6 years), and 31 received transient androgen blockade with a gonadotropin-releasing hormone agonist (4) androgen receptor blocker (1) or both (24) beginning 2 months prior to irradiation (mean follow-up 3.0 years) for a mean duration of 6 months. Two of these patients were excluded from further analysis because they received hormonal therapy for more than 1 year. Patients received a prostatic fossa dose of 60-70 Gy at 2 Gy per fraction; 48 patients also received pelvic nodal irradiation to a median dose of 50 Gy. Survival, freedom from clinical relapse (FFCR), and freedom from biochemical relapse (FFBR) were evaluated by the Kaplan-Meier method. Biochemical relapse was defined as two consecutive PSA measurements exceeding 0.07 ng/ml. Results: At 5 years after irradiation, actuarial survival for all patients was 92%, FFCR was 77%, and FFBR was 34%. FFBR was significantly better among patients who received transient androgen blockade before and during radiotherapy than among those treated with radiation alone (56 vs. 27% at 5 years, p = 0.004). FFCR was also superior for the combined treatment group (100 vs. 70% at 5 Sears, p = 0.014). Potential clinical prognostic factors before irradiation did not differ significantly between treatment groups, including tumor stage, summed Gleason histologic score, lymph node status, indication for treatment, and PSA levels before surgery or subsequent treatment, Multivariate analysis revealed that transient androgen deprivation was the only significant predictor for biochemical failure. Conclusion: This retrospective study of irradiation after radical prostatectomy suggests that transient androgen blockade and irradiation may improve freedom from early biochemical and clinically evident relapse compared to radiotherapy atone, although more prolonged follow-up will be needed to assess durability of impact upon clinical recurrence and survival rates. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:735 / 740
页数:6
相关论文
共 36 条
  • [1] ADJUVANT RADIOTHERAPY FOR PATHOLOGICAL STAGE T3/4 ADENOCARCINOMA OF THE PROSTATE - 10-YEAR UPDATE
    ANSCHER, MS
    ROBERTSON, CN
    PROSNITZ, LR
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 33 (01): : 37 - 43
  • [2] MULTIVARIATE-ANALYSIS OF FACTORS PREDICTING LOCAL RELAPSE AFTER RADICAL PROSTATECTOMY - POSSIBLE INDICATIONS FOR POSTOPERATIVE RADIOTHERAPY
    ANSCHER, MS
    PROSNITZ, LR
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (04): : 941 - 947
  • [3] Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
    Bolla, M
    Gonzalez, D
    Warde, P
    Dubois, JB
    Mirimanoff, RO
    Storme, G
    Bernier, J
    Kuten, A
    Sternberg, C
    Gil, T
    Collette, L
    Pierart, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (05) : 295 - 300
  • [4] Evaluation of serum prostate-specific antigen levels after postoperative radiation therapy for pathologic stage T3, NO prostate cancer
    Buskirk, SJ
    Schild, SE
    Durr, ED
    Robinow, JS
    Bock, FF
    Wolfe, JT
    Tomera, KM
    Ferrigni, RG
    [J]. MAYO CLINIC PROCEEDINGS, 1996, 71 (03) : 242 - 248
  • [5] STAGING ERRORS IN CLINICALLY LOCALIZED PROSTATIC-CANCER
    CATALONA, WJ
    STEIN, AJ
    [J]. JOURNAL OF UROLOGY, 1982, 127 (03) : 452 - 456
  • [6] A CONTROLLED TRIAL OF LEUPROLIDE WITH AND WITHOUT FLUTAMIDE IN PROSTATIC-CARCINOMA
    CRAWFORD, ED
    EISENBERGER, MA
    MCLEOD, DG
    SPAULDING, JT
    BENSON, R
    DORR, FA
    BLUMENSTEIN, BA
    DAVIS, MA
    GOODMAN, PJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (07) : 419 - 424
  • [7] RELATIONSHIP BETWEEN DNA FRAGMENTATION AND APOPTOSIS IN THE PROGRAMMED CELL-DEATH IN THE RAT PROSTATE FOLLOWING CASTRATION
    ENGLISH, HF
    KYPRIANOU, N
    ISAACS, JT
    [J]. PROSTATE, 1989, 15 (03) : 233 - 250
  • [8] DEFINITIVE RADIOTHERAPY FOLLOWING PROSTATECTOMY - RESULTS AND COMPLICATIONS
    FORMAN, JD
    WHARAM, MD
    LEE, DJ
    ZINREICH, ES
    ORDER, SE
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1986, 12 (02): : 185 - 189
  • [9] Forman JD, 1998, ONCOLOGY-NY, V12, P33
  • [10] IS PROSTATE SPECIFIC ANTIGEN OF CLINICAL IMPORTANCE IN EVALUATING OUTCOME AFTER RADICAL PROSTATECTOMY
    FRAZIER, HA
    ROBERTSON, JE
    HUMPHREY, PA
    PAULSON, DF
    [J]. JOURNAL OF UROLOGY, 1993, 149 (03) : 516 - 518